Compare STTK & SPIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | SPIR |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.4M | 533.0M |
| IPO Year | 2020 | 2020 |
| Metric | STTK | SPIR |
|---|---|---|
| Price | $6.95 | $21.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $7.60 | ★ $14.20 |
| AVG Volume (30 Days) | 502.9K | ★ 1.4M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.02 | ★ 134.98 |
| EPS | N/A | ★ 1.49 |
| Revenue | $1,000,000.00 | ★ $110,451,000.00 |
| Revenue This Year | N/A | $11.91 |
| Revenue Next Year | N/A | $23.34 |
| P/E Ratio | ★ N/A | $12.02 |
| Revenue Growth | N/A | ★ 13.15 |
| 52 Week Low | $0.71 | $6.60 |
| 52 Week High | $7.68 | $20.51 |
| Indicator | STTK | SPIR |
|---|---|---|
| Relative Strength Index (RSI) | 65.29 | 73.88 |
| Support Level | $5.75 | $8.05 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.47 | 1.78 |
| MACD | 0.03 | 0.77 |
| Stochastic Oscillator | 61.66 | 97.25 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Spire Global Inc provides space-based data, analytics, and space services, offering datasets and insights about Earth to support decision-making. It builds, owns, and operates a constellation of nanosatellites that observe the Earth in real time using radio frequency (RF) technology. Additionally, it offers Space Services solutions that allow customers to deploy and scale their own satellite constellations using its platform, ground station network, manufacturing facilities, and launch partnerships. The company derives revenue from providing data, insights and access to its cloud-based technology platform sold on a subscription basis.